Press "Enter" to skip to content

PTSD Blood Test; Rapastinel’s Phase III Flop; Discharging the Criminally Insane

Researchers developed a new blood test aimed at diagnosing post-traumatic stress disorder via gene expression signatures. (Molecular Psychiatry)

A systematic review of suicide prediction models found they all stink. (JAMA Psychiatry)

Eisai and Imbrium Therapeutics submitted a U.S. marketing application for their dual orexin receptor antagonist insomnia treatment lemborexant.

Five consecutive days of transcranial alternating current stimulation yielded a slight reduction in depressive symptoms two weeks later. (Translational Psychiatry)

The investigational antidepressant rapastinel — an NMDA receptor modulator distinct from ketamine — failed to meet efficacy endpoints in three phase III trials, according to topline results released by drugmaker Allergan.

Pop music star Taylor Swift said she takes an L-theanine supplement to help combat her anxiety and stress. (Bustle)

The connection between adolescent binge drinking and anxiety later in life may be clearer, thanks to a mouse study. “We identified underlying epigenetic processes regulating Arc eRNA expression in adulthood that are affected by adolescent alcohol exposure,” said lead author Subhash Pandey, PhD, of the University of Illinois at Chicago, in a statement. (Biological Psychiatry)

Head of the Oregon Psychiatric Security Review Board called for a better way to manage people found criminally insane, while they’re institutionalized and after their release. (ProPublica)